JP2011505356A5 - - Google Patents

Download PDF

Info

Publication number
JP2011505356A5
JP2011505356A5 JP2010535919A JP2010535919A JP2011505356A5 JP 2011505356 A5 JP2011505356 A5 JP 2011505356A5 JP 2010535919 A JP2010535919 A JP 2010535919A JP 2010535919 A JP2010535919 A JP 2010535919A JP 2011505356 A5 JP2011505356 A5 JP 2011505356A5
Authority
JP
Japan
Prior art keywords
compound
formula
pharmaceutically acceptable
acceptable salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2010535919A
Other languages
English (en)
Other versions
JP2011505356A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/SE2008/051370 external-priority patent/WO2009070116A1/en
Publication of JP2011505356A publication Critical patent/JP2011505356A/ja
Publication of JP2011505356A5 publication Critical patent/JP2011505356A5/ja
Withdrawn legal-status Critical Current

Links

Description

本発明は、さらに、本発明の化合物、またはその薬学的に許容される塩と、非経腸的または局所的(吸入を含む)に適用する局所麻酔剤、例えばリグノカインまたはその誘導体の組み合わせに関する。

Claims (8)

  1. 式(Ｉ)
    Figure 2011505356
     の化合物、またはその薬学的に許容される塩。
  2. 請求項１に記載の式(Ｉ)の化合物、またはその薬学的に許容される塩を薬学的に許容されるアジュバント、希釈剤または担体と共に含む、医薬組成物。
  3. 請求項１に記載の式(Ｉ)の化合物、またはその薬学的に許容される塩と薬学的に許容されるアジュバント、希釈剤または担体を混合することを含む、請求項２に記載の医薬組成物の製造方法。
  4. 治療に使用するための、請求項１に記載の式(Ｉ)の化合物、またはその薬学的に許容される塩。
  5. リウマチ性関節炎の処置に使用するための医薬の製造における、請求項１に記載の式(Ｉ)の化合物、またはその薬学的に許容される塩の使用。
  6. 炎症性腸疾患またはクローン病の処置に使用するための医薬の製造における、請求項１に記載の式(Ｉ)の化合物、またはその薬学的に許容される塩の使用。
  7. 請求項１に記載の式(Ｉ)の化合物の製造方法であって、式(II)
    Figure 2011505356
     の化合物と、式(III)
    Figure 2011505356
     〔式中、ＰＧは保護基である。〕
    を還元的アミノ化条件下に反応させ、そして
    所望により本化合物の薬学的に許容される塩を形成させることを含む、方法。
  8. 請求項１に記載の化合物を、それを必要とする対象に投与することを含む、当該化合物により治療し得る疾患の処置方法。
JP2010535919A 2007-11-30 2008-11-28 Ｐ２ｘ７受容体アンタゴニストとして作用するキノリン誘導体 Withdrawn JP2011505356A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99126507P 2007-11-30 2007-11-30
PCT/SE2008/051370 WO2009070116A1 (en) 2007-11-30 2008-11-28 A quinoline derivative acting as a p2x7-receptor antagonist

Publications (2)

Publication Number Publication Date
JP2011505356A JP2011505356A (ja) 2011-02-24
JP2011505356A5 true JP2011505356A5 (ja) 2012-02-02

Family

ID=40676391

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010535919A Withdrawn JP2011505356A (ja) 2007-11-30 2008-11-28 Ｐ２ｘ７受容体アンタゴニストとして作用するキノリン誘導体

Country Status (10)

Country Link
US (1) US8106073B2 (ja)
EP (1) EP2225222B1 (ja)
JP (1) JP2011505356A (ja)
AR (1) AR069508A1 (ja)
AT (1) ATE524458T1 (ja)
ES (1) ES2370960T3 (ja)
HK (1) HK1148002A1 (ja)
PE (1) PE20091036A1 (ja)
TW (1) TW200932229A (ja)
WO (1) WO2009070116A1 (ja)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20091225A1 (es) * 2007-03-22 2009-09-16 Astrazeneca Ab Derivados de quinolina como antagonistas del receptor p2x7
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7
BR112012014180A2 (pt) 2009-12-17 2015-09-15 Merck Sharp & Dohme composto, composição farmacêutica, uso da composição farmacêutica, e, método para tratar uma doença ou em distúrbio.
WO2012110190A1 (en) 2011-02-17 2012-08-23 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163792A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
WO2012163456A1 (en) 2011-05-27 2012-12-06 Affectis Pharmaceuticals Ag Novel p2x7r antagonists and their use
TW201309706A (zh) 2011-07-22 2013-03-01 Actelion Pharmaceuticals Ltd 作為ｐ２ｘ７受體拮抗劑之雜環醯胺衍生物
EP2804865B1 (en) 2012-01-20 2015-12-23 Actelion Pharmaceuticals Ltd. Heterocyclic amide derivatives as p2x7 receptor antagonists
BR112015013463B1 (pt) 2012-12-12 2022-06-14 Idorsia Pharmaceuticals Ltd Derivados de carboxamida indol como antagonistas do receptor de p2x7
CA2891499C (en) 2012-12-18 2021-07-06 Actelion Pharmaceuticals Ltd Indole carboxamide derivatives as p2x7 receptor antagonists
KR102220847B1 (ko) 2013-01-22 2021-02-26 이도르시아 파마슈티컬스 리미티드 Ｐ2ｘ7 수용체 길항제로서의 헤테로시클릭 아미드 유도체
WO2014115072A1 (en) 2013-01-22 2014-07-31 Actelion Pharmaceuticals Ltd Heterocyclic amide derivatives as p2x7 receptor antagonists
AU2015269598B2 (en) * 2014-06-05 2019-11-14 Merck Patent Gmbh Novel quinoline derivatives and their use in neurodegenerative diseases
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3352912A (en) 1963-07-24 1967-11-14 Du Pont Adamantanes and tricyclo[4. 3. 1. 1 3.8] undecanes
US3471491A (en) 1967-08-28 1969-10-07 Squibb & Sons Inc Adamantyl-s-triazines
US3464998A (en) 1968-03-04 1969-09-02 Searle & Co Adamantyl esters and amides of pyridinecarboxylic acids
GB1274652A (en) 1968-08-27 1972-05-17 Lilly Industries Ltd Adamantanyl-alkylamine derivatives and their preparation
IL53441A0 (en) 1977-11-22 1978-01-31 Teva Pharma Methyladamantyl hydrazines their preparation and pharmaceutical compositions containing them
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
DE69216873T2 (de) 1991-02-21 1997-08-21 Sankyo Co Benzolderivate zum Fördern der Produktion des Nervenwachstumsfaktors
CA2167154A1 (en) 1993-08-10 1995-02-16 Sarkis Barret Kalindjian Gastrin and cck receptor ligands
BR9507788A (pt) 1994-05-27 1997-09-23 Smithkline Beecham Spa Composto ou solvato ou sal do mesmo processo para a preparação do composto composição farmacêutica antagonista do receptor de NK3 uso do composto uso do antagonista do receptor de NG3 e processo para o tratamento e/ou profilaxia de distúrbios pulmonares e distúrbios convulsivos
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
CZ296163B6 (cs) 1996-05-20 2006-01-11 Karboxyamidy chinolinu jako inhibitory TNF a inhibitory PDE-IV
FR2761358B1 (fr) 1997-03-27 1999-05-07 Adir Nouveaux composes de n-aryl piperidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO1999026927A2 (en) 1997-11-21 1999-06-03 Nps Pharmaceuticals, Inc. Metabotropic glutamate receptor antagonists for treating central nervous system diseases
SE9704544D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SE9704545D0 (sv) 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
SK13422001A3 (sk) 1999-04-09 2002-05-09 Astrazeneca Ab Adamantánové deriváty
CH1196397H1 (de) 1999-06-02 2007-05-31 Nps Pharma Inc Metabotrope Glutamatrezeptorantagonisten zur Behandlung von Krankheiten des zentralen Nervensystems.
KR100733752B1 (ko) 1999-11-26 2007-06-29 시오노기세이야쿠가부시키가이샤 Ｎｐｙｙ５ 길항제
GB0013737D0 (en) 2000-06-07 2000-07-26 Astrazeneca Ab Novel compounds
EP1406628B1 (en) 2001-07-02 2006-03-08 Akzo Nobel N.V. Tetrahydroquinoline derivatives
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
SE0103836D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Novel compounds
CA2468015A1 (en) 2001-11-27 2003-06-05 Merck & Co., Inc. 2-aminoquinoline compounds
SE0200920D0 (sv) 2002-03-25 2002-03-25 Astrazeneca Ab Novel compounds
WO2003087037A1 (en) 2002-04-05 2003-10-23 Merck & Co., Inc. Substituted aryl amides
GB0312609D0 (en) 2003-06-02 2003-07-09 Astrazeneca Ab Novel compounds
SE0302139D0 (sv) 2003-07-28 2003-07-28 Astrazeneca Ab Novel compounds
SE0402925D0 (sv) 2004-11-30 2004-11-30 Astrazeneca Ab Novel Compounds
US20080058309A1 (en) 2006-07-27 2008-03-06 Astrazeneca Ab Novel Compounds 171
PE20091225A1 (es) * 2007-03-22 2009-09-16 Astrazeneca Ab Derivados de quinolina como antagonistas del receptor p2x7
PE20091036A1 (es) 2007-11-30 2009-08-15 Astrazeneca Ab Derivado de quinolina como antagonista del receptor p2x7

Similar Documents

Publication Publication Date Title
JP2011505356A5 (ja)
JP2006182786A5 (ja)
JP2009542613A5 (ja)
JP2018518537A5 (ja)
JP2009502743A5 (ja)
JP2009537498A5 (ja)
JP2013542247A5 (ja)
JP2012532874A5 (ja)
JP2013534248A5 (ja)
JP2020507589A5 (ja)
JP2009513604A5 (ja)
JP2006523216A5 (ja)
JP2013507415A5 (ja)
JP2008539268A5 (ja)
JP2007145875A5 (ja)
JP2013519645A5 (ja)
JP2008195730A5 (ja)
JP2011504903A5 (ja)
EP2039686A4 (en) DIHYDROPYRIMIDIN COMPOUNDS AND THEIR USES IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT AND PREVENTION OF ANTIVIRAL DISEASES
JP2004534850A5 (ja)
JP2011518202A5 (ja)
JP2016534063A5 (ja)
MX2008016134A (es) Derivados de fenol para el tratamiento de enfermedades respiratorias.
JP2015502974A5 (ja)
JP2008545725A5 (ja)